We thank Dr. Kakiuchi and his colleague for their comments on our article, entitled
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's
disease –a systematic review with meta-analysis [
[1]
]. Tumor necrosis factor-α (TNF) antagonists have historically been used as the first
line of biological therapy for moderate-to-severe ulcerative colitis (UC) and Crohn's
disease (CD) due to their first development and approval. However, several factors
necessitate considerations of alternative treatment options, including contraindications
towards TNF antagonists, as approximately two thirds of patients either do not attain
or maintain remission one year after TNF antagonist initiation, [
- Attauabi M.
- Madsen G.R.
- Bendtsen F.
- Seidelin J.B.
- Burisch J.
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's
disease - a systematic review with meta-analysis.
Dig liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2022; 54: 1168-1178https://doi.org/10.1016/j.dld.2021.11.014
[2]
,
[3]
as well as a lower efficacy of subsequent biological therapies after exposure to
TNF antagonists [
[4]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis.Dig liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2022; 54: 1168-1178https://doi.org/10.1016/j.dld.2021.11.014
- Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.Gastroenterology. 2007; 132: 52-65https://doi.org/10.1053/j.gastro.2006.11.041
- Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study.Aliment Pharmacol Ther. 2022; 55: 541-557https://doi.org/10.1111/apt.16723
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.Gastroenterology. 2014; 147 (e3): 618-627https://doi.org/10.1053/j.gastro.2014.05.008
- More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease.Dig Liver Dis. 2023; 55: 298-299https://doi.org/10.1016/j.dld.2022.11.004
- Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists.Clin Gastroenterol Hepatol. 2017; 15 (e5): 229-239https://doi.org/10.1016/j.cgh.2016.08.044
- Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn's disease but not ulcerative colitis.Clin Gastroenterol Hepatol. 2019; 17 (e1): 2497-2505https://doi.org/10.1016/j.cgh.2018.12.040
- Long-term efficacy of vedolizumab for ulcerative colitis.J Crohn's Colitis. 2017; 11: 400-411https://doi.org/10.1093/ecco-jcc/jjw177
- Long-term efficacy of vedolizumab for Crohn's disease.J Crohn's Colitis. 2017; 11: 412-424https://doi.org/10.1093/ecco-jcc/jjw176
- Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study.J Crohn's Colitis. 2021; 15: 1694-1706https://doi.org/10.1093/ecco-jcc/jjab058
Article info
Publication history
Published online: December 01, 2022
Accepted:
November 16,
2022
Received:
November 11,
2022
Identification
Copyright
© 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel diseaseDigestive and Liver DiseaseVol. 55Issue 2
- PreviewWith great interest, we read a systemic review and meta-analysis by Attauabi et al. [1], suggesting that vedolizumab has a favorable efficacy and safety profile in bio-naïve patients with ulcerative colitis (UC) and Crohn's disease than bio-exposed patients. Vedolizumab is a highly safe biologic that selectively acts in the intestinal tract; thus, systemic side reactions are considered unlikely [2]. Patients at higher risk for serious infections, such as children, the elderly, or patients with chronic lung disease, may benefit more from vedolizumab treatment than from immunosuppressants, corticosteroids, or tumor necrosis factor-α (TNF-α) antagonists [3].
- Full-Text
- Preview
